Skip to main content
SpringerLink
Log in

A phase II Trial of Weekly Paclitaxel, 5-Fluorouracil, and Leucovorin as First-Line Treatment for Metastatic Breast Cancer

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Purpose. This phase II multicenter trial evaluated the efficacy and toxicity of weekly paclitaxel, 5-fluorouracil, and leucovorin administered as first-line therapy for metastatic breast cancer.

Patients and methods. The study enrolled 155 women with pathologically confirmed and measurable metastatic adenocarcinoma of the breast. Treatment consisted of paclitaxel 80 mg/m2, 5-fluorouracil 425 mg/m2, and leucovorin 20 mg/m2 administered weekly 4 × per 4-week cycle in the first 40 patients enrolled (group 1), and weekly 3 × per 4-week cycle in the subsequent 115 patients (group 2) enrolled. Hematologic growth factor support was not routinely used. Twenty patients with hepatic dysfunction were enrolled to assess the tolerability of the regimen in this population. All therapies were delivered in an outpatient setting.

Results. The overall response rate was 48%, with 12-month estimated survival rates of 53% and 65% for treatment groups 1 and 2, respectively. Response rates were not statistically different between the two treatment schedules. Therapy was well tolerated when delivered on the every 3 of 4-week schedule, including patients with hepatic involvement and those age ≥ q 65.

Conclusion. Weekly therapy with paclitaxel and 5-fluorouracil with leucovorin is active as first-line therapy for metastatic breast cancer. Use of this regimen should be given consideration, particularly in patients who are not candidates for anthracycline-based therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M: Cancer statistics, 2001. CA Cancer J Clin 51: 15-36, 2001

    Google Scholar 

  2. Ellis MJ, Hayes DF, Lippman ME: Treatment of metastatic breast cancer. In: Haris JR, Lippman ME, Morrow M, Osborne CK (eds) Diseases of the Breast, 2nd edn, Lippincott Williams &; Wilkins, Philadelphia, 2000, pp 749-797

    Google Scholar 

  3. A'Hern RP, Smith IE, Ebbs SR: Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. Br J Cancer 67: 801-805, 1993

    Google Scholar 

  4. Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, Tinazzi A, Liberati A: Cytotoxic and hormonal Weekly paclitaxel/5-FU/leucovorin in MBC 123 treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16: 3439-3460, 1998

    Google Scholar 

  5. Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P, Klaassen U, Namer M, Bonneterre J, Fumoleau P, Winograd B: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer J Clin Oncol 14: 1858-1867, 1996

    Google Scholar 

  6. Seidman AD, Tiersten A, Hudis C, Gollub M, Barrett S, Yao T-J, Lpore J, Gilewski T, Currie V, Crown J, Hakes T, Baselga J, Sklarin N, Moynihan ME, Tong W, Egorin M, Kearns C, Spriggs D, Norton L: Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 13: 2575-2581, 1995

    Google Scholar 

  7. Reichman BS, Seidman AD, Crown JPA, Heelan R, Hakes TB, Lebwohl DE, Gilewski TA, Surbone A, Currie V, Hudis CA, Yao TJ, Klecker R, Jamis-Dow C, Collins J, Quinlivan S, Berkery R, Toomasi F, Canetta R, Fisherman J, Arbuck S, Norton L: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11: 1943-1951, 1993

    Google Scholar 

  8. Seidman AD, Reichman BS, Crown JPA, Yao T-J, CÚrrie V, Hakes TB, Hudis CA, Gilewski TA, Baselga J, Forsythe P, Lepore J, Marks L, Fain K, Souhrada M, Onetto N, Arbuck S, Norton L: Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 13: 1152-1159, 1995

    Google Scholar 

  9. Fountzilas G, Athanassiades A, Giannakakis T, Bafaloukos D, Karakousis K, Dombros N, Kosmidis P, Skarlos D: A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines. Eur J Cancer 32A: 47-51, 1996

    Google Scholar 

  10. Gianni L, Munzone E, Capri G, Villani F, Spreafico C, Tarenzi E, Fulfaro F, Caraceni A, Martini C, Laffranchi A, Valagussa P, Bonadonna G: Paclitaxel in metastatic breast cancer: a trial of two doses by 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 87: 1169-1175, 1995

    Google Scholar 

  11. Abrams JS, Vena DA, Baltz J, Adams J, Montello M, Christian M, Onetto N, Desmond-Hellman S, Canetta R, Friedman MA, Arbuck S: Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial. J Clin Oncol 13: 2056-2065, 1995

    Google Scholar 

  12. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797-1805, 1991

    Google Scholar 

  13. Seidman AD, Hudis C, Albanel J, Tong W, Tepler I, Currie V, Moynahan ME, Theodoulou M, Gollub M, Baselga J, Norton L: Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16: 3353-3361, 1998

    Google Scholar 

  14. Perez EA, Irwin DH, Patel R, Vogel CL, Kirshner J: A large phase II trial of paclitaxel administered as a weekly one hour infusion in patients with metastatic breast cancer. Proc AmSoc Clin Oncol 18: 126a, 1999 (abstract)

    Google Scholar 

  15. Waintraub SE, Cantwell S, DeVries J: Phase II study to evaluate the efficacy of weekly paclitaxel (WP) in patients with metastatic breast cancer (MBC) who have failed prior anthracycline (A) +/-taxane (T) therapy. Proc Am Soc Clin Oncol 19: 121a, 2000 (abstract)

    Google Scholar 

  16. Alvarez AM, Mickiewicz E, Brosio C, Giglio R, Cinat G, Rodger J, Nicolás C: Reinduction of response with weekly Taxol (T) in advanced breast cancer (ABC). Proc Am Soc Clin Oncol 18: 165a, 1999 (abstract)

    Google Scholar 

  17. Sola C, Lluch A, García-Conde J, Salazar R, García T, Montesinos J, Vera R, Benavides M, Climent MA, Homedo J, Alvarez I, Prósper F, Cortés-Funes H, López López JJ: Phase II study of weekly paclitaxel (P) treatment in recurrent breast cancer after high-dose chemotherapy (HDC). Proc Am Soc Clin Oncol 18: 65a, 1999 (abstract)

    Google Scholar 

  18. Mickiewicz E, Alvarez AM, Brosio C, Giglio R, Cinat G, Rodger J, Nicolás C: A promising second line treatment with weekly Taxol (T) in anthracycline recurrent, advanced breast cancer (ABC) patients (PTS). Proc Am Soc Clin Oncol 18: 135a, 1999 (abstract)

    Google Scholar 

  19. Breier S, Lebedinsky C, Ayiviri A, Roffé C, Traine G, Cot C, Politi P: Long-term weekly paclitaxel (P) in metastatic breast cancer (MBC). A phase II trial in pretreated patients (pts). Proc Am Soc Clin Oncol 17: 192a, 1998 (abstract)

    Google Scholar 

  20. Doroshow JH, Leong L, Margolin K, Flanagan B, Goldberg D, Bertrand M, Akman S, Carr B, Odujinrin O, Newman E: Refractory metastatic breast cancer: salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium. J Clin Oncol 7: 439-444, 1989

    Google Scholar 

  21. Swain SM, Lippman ME, Egan EF, Drake JC, Steinberg SM, Allegra CJ: Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 7: 890-899, 1989

    Google Scholar 

  22. Margolin KA, Doroshow JH, Akman SA, Leong LA, Morgan RJ, Raschko JW, Somlo G, Blevins C: Effective initial therapy of advanced breast cancer with fluorouracil and high-dose, continuous infusion calcium leucovorin. J Clin Oncol 10: 1278-1283, 1992

    Google Scholar 

  23. Grem JL, Nguyen D, Monahan BP, Kao V, Geoffroy FJ: Sequence-dependent antagonism between fluorouracil and paclitaxel in human breast cancer cells. Biochem Pharmacol 58: 477-486, 1999

    Google Scholar 

  24. Nicholson B, Paul D, Shyr Y, Garrett M, Hande KR, Johnson DH: Paclitaxel/5-fluorouracil/leucovorin in metastatic breast cancer: a Vanderbilt Cancer Center phase II trial. Semin Oncol 24(suppl 11): s11-20-s11-23, 1997

    Google Scholar 

  25. Klaassen U, Wilke H, Harstrick A, Philippou Pari C, Strumberg D, Neumann K, Eberhardt W, Achterrath W, Lenaz L, Seeber S: Paclitaxel in combination with weekly 24-hour infusional 5-fluorouracil plus leucovorin in the second-line treatment of metastatic breast cancer: results of a phase II study. Ann Oncol 9: 45-50, 1998

    Google Scholar 

  26. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958

    Google Scholar 

  27. Venook AP, Egorin MJ, Rosner GL, Brown TD, Jahan TM, Batist G, Hohl R, Budman D, Ratain M, Kearns CM, Schilsky RL: Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol 16: 1811-1819, 1998

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oncology and Hematology Associates, Inc., Indianapolis, IN, USA

    David M. Loesch

  2. US Oncology, Houston, TX, USA

    Lina Asmar

  3. Cancer Care Associates, Oklahoma City, OK, USA

    Vikki A. Canfield

  4. Cancer Care Associates, Oklahoma City, OK, USA

    Gregory A. Parker

  5. Cancer Center of Kansas, PA, Wichita, KS, USA

    Harry E. Hynes

  6. Oncology Hematology Associates, Pittsburgh, PA, USA

    Peter G. Ellis

  7. Oncology Hematology Associates, Beaver, PA, USA

    William A. Ferri Jr.

  8. Fairfax-Prince William Hematology-Oncology PC, Annandale, VA, USA

    Nicholas J. Robert

Authors
  1. David M. Loesch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lina Asmar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vikki A. Canfield
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gregory A. Parker
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Harry E. Hynes
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Peter G. Ellis
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. William A. Ferri Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nicholas J. Robert
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Loesch, D.M., Asmar, L., Canfield, V.A. et al. A phase II Trial of Weekly Paclitaxel, 5-Fluorouracil, and Leucovorin as First-Line Treatment for Metastatic Breast Cancer. Breast Cancer Res Treat 77, 115–123 (2003). https://doi.org/10.1023/A:1021384318470

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1021384318470

Search

Navigation